{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T14:10:04Z","timestamp":1748095804494,"version":"3.41.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,24]]},"DOI":"10.7759\/cureus.84736","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T13:39:54Z","timestamp":1748093994000},"source":"Crossref","is-referenced-by-count":0,"title":["Systemic Inflammatory Response Syndrome Following High-Dose Intravenous Glutathione-Containing Revitalising Solution in a Patient on Tirzepatide: A Case Report"],"prefix":"10.7759","author":[{"given":"Deepak","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarala","family":"Daram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyanka","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7196\/SAMJ.2016.v106i8.10878","article-title":"Intravenous glutathione for skin lightening: inadequate safety data","volume":"106","author":"Davids LM","year":"2016","unstructured":"Davids LM, Van Wyk JC, Khumalo NP. Intravenous glutathione for skin lightening: inadequate safety data. S Afr Med J. 2016, 106:782-6. 10.7196\/SAMJ.2016.v106i8.10878","journal-title":"S Afr Med J"},{"key":"ref2","unstructured":"Philippine Food and Drug Administration. FDA Advisory No. 2019-182. Unsafe use of glutathione as skin lightening agent. (2019). Accessed: May 12, 2025: https:\/\/www.fda.gov.ph\/fda-advisory-no-2019-182-unsafe-use-of-glutathione-as-skin-lightening-agent\/."},{"key":"ref3","unstructured":"US Food and Drug Administration. FDA highlights concerns with using the dietary ingredient glutathione to compound sterile injectable drugs. (2019). Accessed. May 12, 2025: https:\/\/www.fda.gov\/drugs\/human-drug-compounding\/fda-highlights-concerns-using-dietary-ingredient-glutathione-compoun...."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2025.03.008","article-title":"The promise of tirzepatide: a narrative review of metabolic benefits","volume":"19","author":"Sokary S","year":"2025","unstructured":"Sokary S, Bawadi H. The promise of tirzepatide: a narrative review of metabolic benefits. Prim Care Diabetes. 2025, 19:229-37. 10.1016\/j.pcd.2025.03.008","journal-title":"Prim Care Diabetes"},{"key":"ref5","unstructured":"Koovika | Glutax 75GX DCRP 750000 DNA Cell Revitalize 14 Sessions Injection. Accessed. May 12, 2025: https:\/\/www.koovika.com\/product-page\/glutax-75gx-dcrp-750000-dna-cell-revitalize-14-sessions-injection."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/134.3.489","article-title":"Glutathione metabolism and its implications for health","volume":"134","author":"Wu G","year":"2004","unstructured":"Wu G, Fang YZ, Yang S, Lupton JR, Turner ND. Glutathione metabolism and its implications for health. J Nutr. 2004, 134:489-92. 10.1093\/jn\/134.3.489","journal-title":"J Nutr"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268818000420","article-title":"Seven cases of probable endotoxin poisoning related to contaminated glutathione infusions","volume":"146","author":"Johnstone T","year":"2018","unstructured":"Johnstone T, Quinn E, Tobin S, Davis R, Najjar Z, Battye B, Gupta L. Seven cases of probable endotoxin poisoning related to contaminated glutathione infusions. Epidemiol Infect. 2018, 146:931-4. 10.1017\/S0950268818000420","journal-title":"Epidemiol Infect"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.105506","article-title":"The dangerous liaisons in innate immunity involving recombinant proteins and endotoxins: examples from the literature and the Leptospira field","volume":"300","author":"Bonhomme D","year":"2024","unstructured":"Bonhomme D, Cavaillon JM, Werts C. The dangerous liaisons in innate immunity involving recombinant proteins and endotoxins: examples from the literature and the Leptospira field. J Biol Chem. 2024, 300:105506-10. 10.1016\/j.jbc.2023.105506","journal-title":"J Biol Chem"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.78045","article-title":"Exploring the safety and efficacy of glutathione supplementation for skin lightening: a narrative review","volume":"17","author":"Alzahrani TF","year":"2025","unstructured":"Alzahrani TF, Alotaibi SM, Alzahrani AA, et al.. Exploring the safety and efficacy of glutathione supplementation for skin lightening: a narrative review. Cureus. 2025, 17:e78045. 10.7759\/cureus.78045","journal-title":"Cureus"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/jbcr\/iraf027","article-title":"Intravenous glutathione and vitamin supplementation causing Stevens-Johnsons syndrome: a case report","author":"Johnson JS","year":"2025","unstructured":"Johnson JS, Jarvis NR, Martinez AM, Dvorak JE. Intravenous glutathione and vitamin supplementation causing Stevens-Johnsons syndrome: a case report. J Burn Care Res. 2025, iraf027. 10.1093\/jbcr\/iraf027","journal-title":"J Burn Care Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.18231\/j.ijced.2024.057","article-title":"Analysis of usage pattern of glutathione by dermatologists: results of a cross-sectional study","volume":"10","author":"Patil A","year":"2024","unstructured":"Patil A, Naseem A, Shukla R, Agrawal B, Langade D. Analysis of usage pattern of glutathione by dermatologists: results of a cross-sectional study. IP Indian J Clin Exp Dermatol. 2024, 10:323-7. 10.18231\/j.ijced.2024.057","journal-title":"IP Indian J Clin Exp Dermatol"},{"key":"ref13","article-title":"Efficacy of intravenous glutathione vs. placebo for skin tone lightening","volume":"26","author":"Zubair R","year":"2016","unstructured":"Zubair R, Mujtaba G, Rasheed F. Efficacy of intravenous glutathione vs. placebo for skin tone lightening. J Pak Assoc Dermatol. 2016, 26:177-181.","journal-title":"J Pak Assoc Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/371457-systemic-inflammatory-response-syndrome-following-high-dose-intravenous-glutathione-containing-revitalising-solution-in-a-patient-on-tirzepatide-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T13:39:55Z","timestamp":1748093995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/371457-systemic-inflammatory-response-syndrome-following-high-dose-intravenous-glutathione-containing-revitalising-solution-in-a-patient-on-tirzepatide-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,24]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.84736","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,24]]}}}